Navigation Links
Second opinion changes diagnosis from incurable to curable cancer
Date:5/12/2014

AURORA, Colo. (May 5, 2014) - The Journal of Clinical Oncology reports the case of a woman diagnosed with advanced, incurable lung cancer, whose disease was in fact early stage, curable lung cancer with additional lung lesions due to a rare antibiotic side effect. When her primary lung tumor was surgically removed, and the antibiotic stopped, the 62-year-old woman recovered and may now be cured.

"In a good example of collaboration with our local oncology community, my colleague wanted a second opinion to ensure his patient got the best possible treatment plan established from the get-go, said Ross Camidge, MD, PhD, director of the thoracic oncology clinical program at the University of Colorado Cancer Center and the senior author of the study. "Initially, they were probably looking for some kind of molecular profiling and possibly a novel drug or combination of drugs in a clinical trial. Instead, through some great teamwork, we were able to reveal something unexpected and radically change her prognosis."

The patient, a former smoker, visited her doctor with a cough, fatigue and weight loss. Her scans revealed a dominant mass in her right lung with multiple smaller nodules and infiltrates throughout both lungs. The biggest mass was biopsied and showed non-small cell lung cancer. Because the disease appeared throughout both lungs, the patient appeared to have advanced stage or metastatic lung cancer, a condition which nationally, is associated with a 5-year survival rate of less than 3 percent.

"But then Eiko Browning, MD, our outstanding senior trainee in oncology, began to notice a series of clues that something else was happening," said Camidge.

First, there were changes in the patient's blood tests showing some damage to the liver, but there were no signs of cancer in the liver. Second, the CU team noticed she also had a long history of urinary tract infections treated with the antibiotic, nitrofurantoin.

Nicole Restauri, MD, the CU radiologist reviewing the scans, then pointed out the little known fact that about one in 100,000 women who take nitrofurantoin experience unusual side effects, including liver and lung damage. Consequently, Camidge and colleagues hypothesized that toxicity due to the antibiotic, and not spread of the lung cancer, could have created the appearance of widespread lung abnormalities. To prove this, they stopped the antibiotic and simply repeated the scans and blood tests a few weeks later. When the liver tests returned to normal and everything except the known lung cancer had disappeared from her scans, the team was able to change her diagnosis from incurable, metastatic lung cancer to early stage, curable lung cancer.

"The prompt, correct diagnosis dramatically changed this patient's care," Camidge said. "Instead of suggesting that this patient undergo standard chemotherapy or treatment in clinical trials, we simply performed surgery. She is now in long-term follow-up care with no evidence of cancer recurrence to date."

Camidge goes on to say, "This is a great example of a community oncologist pushing for the best treatment plan for their patient by actively seeking out a second opinion before commencing treatment. While not always this dramatic, this certainly illustrates the full extent of what a second opinion from an expert multi-disciplinary team can accomplish. When you are dealing with something as serious as cancer, getting another set of eyes to look things over early on can sometimes pay huge dividends."


'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
303-724-1528
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Round 2: Reactions serves up a second helping of chemistry life hacks (video)
2. Second largest research award at Notre Dame fights malaria and dengue fever
3. Immune cells need a second opinion
4. Secondhand smoke exposure increases odds of hospital asthma readmission for children
5. Sound Relief Hearing Center Announces the Winner of Their Second Annual "Gift of Better Hearing" Contest
6. MDA Awards Second 'Bridge-to-Industry' Grant
7. Study Documents Secondhand Exposure to Nicotine from Electronic Cigarette Vapor
8. First-annual Connecticut Cannabis Exposition Arrives in The Nutmeg States' Second Largest City, New Haven
9. The Russian Banya, a Second Mother
10. US Freedom Capital Announces Second Regional Center
11. Mount Sinai Makes Innovation a Team Effort At Its Second Annual Sinainnovations Conference, November 18-19, 2013 In NYC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially ... their medication by matching users with high quality water pipes within an ideal price ... commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, who use ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
(Date:6/23/2016)... , ... June 23, 2016 , ... Representatives of CHA ... the newest member of their staff, Dr. Joshua J. Berger. As of May ... of the world-renowned facility. , Dr. Berger has received recognition for his research, his ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: